Compare WOR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | RCUS |
|---|---|---|
| Founded | 1955 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 1994 | 2018 |
| Metric | WOR | RCUS |
|---|---|---|
| Price | $56.35 | $31.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $59.50 | $31.90 |
| AVG Volume (30 Days) | 230.7K | ★ 1.4M |
| Earning Date | 03-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $1,153,762,000.00 | $247,000,000.00 |
| Revenue This Year | $22.21 | N/A |
| Revenue Next Year | $6.03 | $45.62 |
| P/E Ratio | $25.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.01 | $7.92 |
| 52 Week High | $67.80 | $31.44 |
| Indicator | WOR | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 73.95 |
| Support Level | $51.93 | $19.78 |
| Resistance Level | $56.13 | N/A |
| Average True Range (ATR) | 1.90 | 1.63 |
| MACD | -0.49 | 0.77 |
| Stochastic Oscillator | 21.90 | 90.94 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.